Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. · 2013
Read Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. by Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3906841.txt.
Introduction
H. J. Lambers Heerspink, D. de Zeeuw, L. Wie, B. Leslie, and J. List report a randomized trial in Diabetes, Obesity and Metabolism in 2013. Their question was whether dapagliflozin, a drug that makes the kidneys release more glucose, also acts like a diuretic in people with type 2 diabetes. They compared it with hydrochlorothiazide, a standard water pill, and with placebo.
Seventy-five adults took part for twelve weeks, and blood pressure, weight, plasma volume, and kidney filtration were tracked. Dapagliflozin lowered blood pressure modestly, reduced weight, and cut the filtration rate more than placebo, while plasma volume seemed to fall in a smaller sub-study. The authors read these results as signs that the drug has diuretic-like effects on top of its glucose control.
Catalog record
| CREATOR | Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. |
|---|---|
| YEAR | 2013 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes By H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List Published in: Diabetes, Obesity & Metabolism DOI: 10.1111/dom.12127 ABSTRACT Abstract Aims Sodium–glucose co-transporter 2 (SGLT2) reabsorbs glucose and sodium in the renal proximal tubule. Dapagliflozin, an SGLT2 inhibitor, targets hyperglycaemia in type 2 diabetes by increasing renal glucose excretion. To investigate whether the parallel occurring sodium loss would have diuretic-like physiologic effects, we compared dapagliflozin and hydrochlorothiazide (HCTZ) effects on 24-h blood pressure (BP), body weight, plasma volume and glomerular filtration rate (GFR). Methods In this randomized, placebo-controlled, double-blind trial, 75 subjects with type 2 diabetes were assigned placebo, dapagliflozin 10 mg/day, or HCTZ 25 mg/day. Changes from baseline BP, body weight, plasma volume and GFR were assessed after 12 weeks of treatment. Results Subjects’ mean age was 56 years, type 2 diabetes mellitus (T2DM) duration 6.3 years, and haemoglobin A1c (HbA1c) 7.5%. Treatment with placebo, dapagliflozin or HCTZ resulted in changes from baseline in 24-h ambulatory mean systolic blood pressure (SBP) of −0.9 (95%CI −4.2, +2.4), −3.3 (95%CI −6.8, +0.2), and −6.6 (95%CI −9.9, −3.2) mmHg, respectively at week 12, adjusted for baseline SBP. Body weight decreased with dapagliflozin and HCTZ. In a sub-study plasma volume appeared to decrease with dapagliflozin but did not change with placebo or HCTZ treatment. Dapagliflozin induced a greater reduction in GFR (−10.8%; 95%CI −14.6, −6.7) relative to placebo (−2.9%; 95% CI −6.9, +1.2) or HCTZ (−3.4%; 95%CI −7.3, +0.6). Conclusions Dapagliflozin-induced SGLT2 inhibition for 12 weeks is associated with reductions in 24-h BP, body weight, GFR and possibly plasma volume. Cumulatively, these effects suggest that dapagliflozin may have a diuretic-like capacity to lower BP in addition to beneficial effects on glycaemic control. Keywords: blood pressure, dapagliflozin, HbA1c, renal function, type 2 diabetes INTRODUCTION Many patients with diabetes present with hyperglycaemia, hypertension, hypercholesterolemia and excess weight, which are associated with micro- and macrovascular complications. Therapies to alleviate the burden of these complications have traditionally focused on reducing glycaemia and optimizing blood pressure (BP) and cholesterol concentration. However, despite the various available treatment options to improve glycaemic control, many patients do not reach treatment targets. In addition, sulphonylurea derivatives and glitinides, which increase secretion of insulin, are associated with clinically important side effects such as weight gain and hypoglycaemia 1,2. Novel treatment strategies are therefore required that aid in achieving therapeutic targets without inducing weight gain or hypoglycaemia. Emerging insight in the role of the sodium–glucose co-transporter 2 (SGLT2) in glucose reabsorption in the kidney has led to the development of selective orally available sodium–glucose transport inhibitors. These drugs are designed to inhibit SGLT2 located mainly in the S1-segment of the proximal tubule 4. This inhibition augments urinary glucose excretion, which has proved successful in reducing plasma glucose and haemoglobin A1c (HbA1c) 5,6. Inhibiting SGLT2, however, also leads to reduced sodium reabsorption in the proximal tubule; this can enhance sodium excretion. In previous studies 8,9 dapagliflozin administration has been associated with decreases in body weight and BP. Furthermore, dose-related increases in haematocrit and decreases in creatinine clearance were seen in dapagliflozin-treated patients 8. These observations suggest that a natriuretic effect of dapagliflozin may be associated with a ‘diuretic-like’ antihypertensive action. The aim of this study was to assess whether dapagliflozin has diuretic-like effects along with its glucose-lowering effect. To this end, we determined the effects of dapagliflozin, hydrochlorothiazide and placebo on BP, body weight, plasma volume and renal function using dedicated measurement techniques. METHODS This was a multicenter, randomized, double-blind, three-arm, parallel-group, placebo- and active-controlled study conducted from October 2009 to July 2010 in Canada, The Netherlands and the USA. It is registered with http://www.clinicaltrials.gov (NCT00976495). Patients Eligible patients were men and women with type 2 diabetes aged between 18 and 70 years, who had inadequate glycaemic control, defined as HbA1c ≥6.6% and ≤9.5%, and who were receiving a stable dose of metformin and/or a sulfonylurea derivative for at least 4 weeks prior to study entry. Subjects had to have an enrollment C-peptide ≥ 0.27 nmol/l, an estimated glomerular filtration rate (GFR) >60 ml/min/1.73 m2 and <150 ml/min/1.73 m2, urine albumin : creatinine ratio <300 mg/g, body mass index ≤45.0 kg/m2, and inadequate BP control, defined as systolic blood pressure (SBP) ≥130 and <165 mmHg, and/or diastolic BP ≥80 and <105 mmHg. Subjects with type 1 diabetes, those with cardiovascular disease within 6 months of study entry, and pregnant women were excluded from study participation. Subjects with a history of adverse reaction to radiocontrast dye, or allergy to or contraindication for thiazide diuretics were excluded as well. All subjects gave written informed consent prior to enrollment in the study. The study was approved by the appropriate local research ethics committee and was performed in accordance with the Declaration of Helsinki of the World Medical Association. Design The study consisted of a 14-day qualification period, a 7-day single-blind lead-in period, and a double-blind treatment period of 12 weeks. A qualification assessment was performed in all patients that included a complete medical history, safety, laboratory measurements and pregnancy test for women of childbearing potential. Subjects maintained their stable dose of metformin and/or sulphonylurea derivatives. Subjects who were receiving a stable dose of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) continued these medications. Subjects received dietary counseling during the lead-in period and throughout the study. Twenty-four-hour ambulatory BP monitoring was initiated at the start of the lead-in period. Those patients who met the inclusion criteria and adhered to study medication were randomly assigned to dapagliflozin 10 mg/day, hydrochlorothiazide 25 mg/day, or matched placebo in a 1 : 1 : 1 ratio. Hydrochlorothiazide was chosen as active comparator as it is the most commonly used thiazide diuretic. Study treatments were allocated using a central, computer-based randomization procedure. Blinding of patients and investigators to study treatment was achieved using a double-dummy technique. Randomization was stratified globally by prior antihypertensive drug use (ACEI or ARB, or no antihypertensive drug) as well as participation in the red cell mass/plasma volume substudy. The doses of metformin and sulphonylurea derivatives as well as ACEI or ARB, if applicable, were maintained stable for the duration of the double-blind treatment period. Patients attended the clinic 1, 2, 4, 8 and 12 weeks after randomization. At each follow-up visit, efficacy and safety parameters were measured. Measurements BP was measured by 24-h ambulatory BP monitoring (Spacelabs 90207 BP monitor). GFR was determined by plasma disappearance of iohexol. After a 5-ml bolus iohexol infusion (300 mg iodine/ml) blood samples were taken until 4 h after the iohexol infusion. Plasma iohexol concentrations were measured at a central laboratory (Karolinska Institute, Uppsala, Sweden) by high-performance liquid chromatography. Plasma iohexol was calculated according to a one-compartment model to obtain GFR (after correction according the Brochner–Mortensen formula and body surface area) 10. In subjects receiving metformin, the dose of metformin was withheld on the visit day of the GFR procedure until at least 48 h after the GFR procedure according the metformin label which directs that metformin should be temporarily discontinued prior to any intravascular radiocontrast study. Estimated GFR (eGFR) was calculated with the MDRD-formula. Plasma volume and red cell mass were simultaneously estimated